0Z2 Stock Chart & Stats
€1.31
<€0.01(0.23%)
At close: 4:00 PM EDT
€1.31
<€0.01(0.23%)
Day’s Range― - ―
52-Week Range€0.96 - €2.86
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€225.51M
Enterprise Value€83.52
Total Cash (Recent Filing)€172.80M
Total Debt (Recent Filing)€32.76M
Price to Earnings (P/E)―
Beta1.41
Next Earnings
Nov 10, 2026EPS Estimate
-0.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.10
Shares Outstanding111,656,920
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-0.09
Price to Book (P/B)5.24
Price to Sales (P/S)7.63
P/FCF Ratio-0.87
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€2.04Price Target Upside55.52% Upside
Rating ConsensusHold
Number of Analyst Covering6
EPS Forecast (FY)-0.75
Revenue Forecast (FY)€8.63M
Bulls Say, Bears Say
Bulls Say
Specialized Immuno-neurology PlatformA focused immuno-neurology strategy gives Alector scientific specialization in high-need diseases, with the potential to reuse biological insights and development capabilities across Alzheimer’s disease and frontotemporal dementia programs.
Hercules Debt RetiredEliminating the Hercules facility reduces contractual debt obligations and interest-related pressure, giving Alector greater flexibility to prioritize remaining clinical programs and manage financing needs while its pipeline is reassessed.
Shareholder And Governance ContinuityApproval of the board slate, auditor, and executive compensation indicates continued shareholder support for governance arrangements. This can help preserve operational continuity as management restructures the pipeline and partnership strategy.
Bears Say
Clinical Pipeline And Partnership SetbacksTwo important clinical setbacks and the loss of GSK remove validation, development resources, and potential milestone support. The termination leaves Alector with a narrower pipeline and greater responsibility for future funding and execution.
Sustained Cash BurnLarge recurring cash outflows relative to revenue increase dependence on collaboration proceeds or external financing. Without a commercial product, sustained burn could constrain trial activity and raise dilution or funding risk over the next several quarters.
Negative Equity And Weak Earnings ProfileNegative equity and deeply negative profitability indicate limited financial resilience, while declining revenue reduces internal funding capacity. The combination makes it harder to absorb further development failures or replace lost partnership economics.
Alector News
0Z2 FAQ
What was Alector Inc’s price range in the past 12 months?
Alector Inc lowest stock price was €0.95 and its highest was €2.86 in the past 12 months.
What is Alector Inc’s market cap?
Alector Inc’s market cap is €225.51M.
When is Alector Inc’s upcoming earnings report date?
Alector Inc’s upcoming earnings report date is Nov 10, 2026 which is in 72 days.
How were Alector Inc’s earnings last quarter?
Alector Inc released its earnings results on Aug 06, 2026. The company reported -€0.181 earnings per share for the quarter, beating the consensus estimate of -€0.198 by €0.016.
Is Alector Inc overvalued?
According to Wall Street analysts Alector Inc’s price is currently Undervalued.
Does Alector Inc pay dividends?
Alector Inc does not currently pay dividends.
What is Alector Inc’s EPS estimate?
Alector Inc’s EPS estimate is -0.2.
How many shares outstanding does Alector Inc have?
Alector Inc has 111,656,920 shares outstanding.
What happened to Alector Inc’s price movement after its last earnings report?
Alector Inc reported an EPS of -€0.181 in its last earnings report, beating expectations of -€0.198. Following the earnings report the stock price went up 20.553%.
Which hedge fund is a major shareholder of Alector Inc?
Currently, no hedge funds are holding shares in DE:0Z2
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Alector Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
€2.04 (55.52% Upside)
€2.04 (55.52% Upside)
Blogger Sentiment
Neutral
DE:0Z2 Sentiment 100%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth €190.9K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-14.20%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-43.09%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Alector Inc
Alector, Inc. operates as a clinical-stage biopharmaceutical company, which engages in pioneering of immuno-neurology. It develops portfolio of innate immune system programs, designed to functionally repair genetic mutations and enable the rejuvenated immune cells to counteract emerging brain pathologies. Its treatment targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. The company was founded by Asa Abeliovich, Errik B. Anderson, Tillman U. Gerngross, and Arnon Rosenthal in May 2013 and is headquartered in South San Francisco, CA.
0Z2 Stock 12 Month Forecast
Average Price Target
€2.04
▲(55.52% Upside)